This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citing articles on ISI (3)  • Contact me when this article is cited  Related Content  • Related article  • Similar articles in this journal  Topic Collections  • Dermatologic Disorders, Other  • Drug Therapy  • Adverse Effects  • Alert me on articles by topic

Arch Dermatol. 2003;139:89-90.

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

IN 1985, Reed et al¹ published the first case series of subacute cutaneous lupus erythematosus (SCLE) that was linked to the administration of a drug. They reported that the onset of the cutaneous eruption occurred during the administration of hydrochlorothiazide treatment and resolved with its discontinuation. In addition, 1 of their patients was treated with a second administration of hydrochlorothiazide that was followed by a reappearance of the eruption, which then cleared again with discontinuation of treatment with the offending drug. Their patients were anti-Ro/SSA positive, and in 1 of the 3 patients subsequently tested, the antibody disappeared.

In 1986, my colleagues and I reported our experience with SCLE.² Following the initial review of our manuscript, we were asked by one of the reviewers to assess the potential occurrence of drug-induced disease in our group of patients. At that time we did not find any case of drug-induced or drug-worsened . . . [Full Text of this Article]

RELATED ARTICLE

Drug-Induced, Ro/SSA-Positive Cutaneous Lupus Erythematosus
Monika Srivastava, Adrienne Rencic, Gerardine Diglio, Helen Santana, Paula Bonitz, Rosemarie Watson, Esther Ha, Grant J. Anhalt, Thomas T. Provost, and Carlos H. Nousari
Arch Dermatol. 2003;139(1):45-49.
ABSTRACT | FULL TEXT